Skip to main content
Clinical Trials/NCT01214811
NCT01214811
Completed
Phase 3

Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing

Molnlycke Health Care AB3 sites in 1 country27 target enrollmentSeptember 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Inflammation
Sponsor
Molnlycke Health Care AB
Enrollment
27
Locations
3
Primary Endpoint
Wound Are at Baseline
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the change in signs of inflammation/local infection when Mepilex Border Ag is used in normal clinical practice when used on chronic ulcers (venous leg, diabetic foot and pressure ulcers) and partial thickness burns in need* of topical antimicrobial treatment according to the physician.

Detailed Description

The investigation is designed as an open, non-controlled, post-marketing clinical follow-up. Subjects with chronic ulcers or partial thickness burns (including donor sites) at 2 sites will be included. Each subject with a chronic ulcer will be seen once a week for a maximum of 4 weeks or until desired treatment effect is obtained, whichever occurs earlier. Each subject with a partial thickness burn/donor site will be followed once a week for a maximum of 3 weeks or until desired treatment effect is obtained, whichever occurs earlier. All dressing changes will be done according to clinical routine practices and will follow IFU (instruction for use)

Registry
clinicaltrials.gov
Start Date
September 2010
End Date
December 2011
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Molnlycke Health Care AB
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject with a chronic ulcer (venous leg, diabetic foot and pressure ulcers) or a partial thickness burn where an antimicrobial action is indicated\* as judged by the investigator
  • Male or female, 18 years and above, both in- and out-patients
  • Signed Informed Consent Form

Exclusion Criteria

  • Wound size equal to or above 9.5x15cm for the wound/burn to be included in the investigation
  • Subject not expected to follow the investigation procedures
  • TBSA \> 10% (partial thickness burns only)
  • HbA1C value \> 7.
  • (To be measured if BMI \> 30)
  • Pregnant and breastfeeding women
  • Pressure ulcers deeper than stage 3
  • Deep pressure ulcers in need of a filler
  • Subjects with known sensitivity to silver or any other dressing materials
  • Subjects receiving radiation treatment or examinations e.g. X-ray, ultrasound, diathermy or Magnetic Resonance Imaging

Outcomes

Primary Outcomes

Wound Are at Baseline

Time Frame: Baseline

Wound Area at Visit 2

Time Frame: After one week

At each visit the wound length and width is measured and calculated in cm2.

Study Sites (3)

Loading locations...

Similar Trials